Hedgehog signaling sensitizes Glioma stem cells to endogenous nano-irradiation

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5483-5493

  Morgenroth, Agnieszka ^a   Vogg, Andreas T J ^a   Ermert, Katja ^a   Zlatopolskiy, Boris ^a,b   Mottaghy, Felix M ^a,c  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Auger electron emitter; Glioma stem cells; Hedgehog; Nano irradiation; Thymidine analogue

Indexed keywords

5 IODO 4' THIO 2' DEOXYURIDINE I 125; ANTINEOPLASTIC AGENT; CASPASE 3; FLOXURIDINE; PROTEIN PATCHED 1; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; 5-IODO-4'-THIO-2'-DEOXYURIDINE; DEOXYURIDINE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

APOPTOSIS; ARTICLE; ASTROCYTE; CANCER CELL DESTRUCTION; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; DRUG MECHANISM; ENDOGENOUS NANO IRRADIATION; G2 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA CELL LINE; GLIOMA STEM CELL; HEDGEHOG PATHWAY; HUMAN; HUMAN CELL; MITOGENESIS; MITOSIS; PROTEIN SYNTHESIS REGULATION; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; STIMULATION; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; GLIOBLASTOMA; METABOLISM; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE;

APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYURIDINE; GLIOBLASTOMA; HEDGEHOG PROTEINS; HUMANS; IODINE RADIOISOTOPES; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; RADIOPHARMACEUTICALS; SIGNAL TRANSDUCTION;

EID: 84906264373     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2123     Document Type: Article

References (45)

1. Omuro A and DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310: 1842-1850.
2. Johnson DR and O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012; 107: 359-364.
3. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004; 432: 396-401.
4. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004; 64: 7011-7021.
5. Singh SK, Clarke ID, Hide T and Dirks PB. Cancer stem cells in nervous system tumors. Oncogene. 2004; 23: 7267-7273.
6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444: 756-760.
7. Clement V, Sanchez P, de Tribolet N, Radovanovic I and Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007; 17: 165-172.
8. Varjosalo M and Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008; 22: 2454-2472.
9. Riobó NA, Lu K, Ai X, Haines MH and Emerson CPJ. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. PNAS. 2006; 103: 4505-4510.
10. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, Xu W, Cui C, Xing Y, Liu Y, Cao B, Liu C, Wu G, Ao H, Zhang X and Jiang J. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. PNAS. 2013; 110: 6829-6834.
11. Dave RK, Ellis T, Toumpas MC, Robson JP, Julian E, Adolphe C, Bartlett PF, Cooper HM, Reynolds BA and Wainwright BJ. Sonic hedgehog and notch signaling can cooperate to regulate neurogenic divisions of neocortical progenitors. Plos One. 2011; 6: e14680.
12. Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W, Grasmo-Wendler UH, Myklebost O, Helseth E, Vik-Mo EO, Hide W and Langmoen IA. Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt-signaling and a fingerprint associated with clinical outcome. Exp Cell Res. 2013; 319: 2230-2243.
13. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES and Golub TR. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002; 415: 436-442.
14. Schiapparelli P, Shahi MH, Enguita-Germán M, Johnsen JI, Kogner P, Lázcoz P and Castresana JS. Inhibition of the sonic hedgehog pathway by cyplopamine reduces the CD133+/CD15+ cell compartment and the in vitro tumorigenic capability of neuroblastoma cells. Cancer Lett. 2011; 310: 222-231.
15. Huang FT, Zhuan-Sun YX, Zhuang YY, Wei SL, Tang J, Chen WB and Zhang SN. Inhibition of hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance. Int J Oncol. 2012; 41: 1707-1714.
16. Morgenroth A, Vogg AT, Mottaghy FM and Schmaljohann J. Targeted endoradiotherapy using nucleotides. Methods. 2011; 55: 203-214.
17. Toyohara J, Hayashi A, Sato M, Tanaka H, Haraguchi K, Yoshimura Y, Yonekura Y and Fujibayashi Y. Rationale of 5-(125)I-iodo-4'-thio-2'-deoxyuridine as a potential iodinated proliferation marker. J Nucl Med. 2002; 43: 1218-1226.
18. Morgenroth A, Deisenhofer S, Glatting G, Kunkel FH, Dinger C, Zlatopolskiy B, Vogg AT, Kull T and Reske SN. Preferential tumor targeting and selective tumor cell cytotoxicity of 5-[131/125I]iodo-4'-thio-2'-deoxyuridine. Clin Cancer Res. 2008; 14: 7311-7319.
19. Toyohara J, Gogami A, Hayashi A, Yonekura Y and Fujibayashi Y. Pharmacokinetics and metabolism of 5-125I-iodo-4'-thio-2'-deoxyuridine in rodents. J Nucl Med. 2003; 44: 1671-1676.
20. Reske SN, Deisenhofer S, Glatting G, Zlatopolskiy BD, Morgenroth A, Vogg AT, Buck AK and Friesen C. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines. J Nucl Med. 2007; 48: 1000-1007.
21. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA and Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111: 2516-2520.
22. Mohrin M, Bourke E, Alexander D, Warr MR, Barry-Holson K, Le Beau MM, Morrison CG and Passegué E. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell. 2010; 7: 174-185.
23. Kassis AL. The amazing world of auger electrons. Int J Radiat Biol. 2004; 80: 789-803.
24. Morgenroth A, Vogg AT, Zlatopolskiy BD, Siluschek M, Oedekoven C and Mottaghy FM. Breaking the invulnerability of cancer stem cells: two-step strategy to kill the stem-like cell subpopulation of multiple myeloma. Mol Cancer Res. 2014; 13: 144-153.
25. Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S and Kornblum HI. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells. 2009; 27: 980-987.
26. Zhou BB and Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000; 408: 433-439.
27. Dean M, Fojo T and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5: 275-284.
28. Ruiz i Altaba A, Stecca B and Sánchez P. Hedgehog-Gli signaling in brain tumors: stem cells and paradevelopmental programs in cancer. Cancer Lett. 2004; 204: 145-157.
29. Dahmane N, Lee J, Robins P, Heller P and Ruiz i Altaba A. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature. 1997; 389: 876-881.
30. Palma V, Lim DA, Dahmane N, Sánchez P, Brionne TC, Herzberg CD, Gitton Y, Carleton A, Alvarez-Buylla A and Ruiz i Altaba A. Sonic hedgehog controls stem cell behavior in the postnatal and adult brain. Development. 2005; 132: 335-344.
31. Sanai N, Tramontin AD, Quiñones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S, Lawton MT, McDermott MW, Parsa AT, Manuel-García Verdugo J, Berger MS and Alvarez-Buylla A. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature. 2004; 427: 740-744.
32. Beier D, Röhrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wischhusen J, Reifenberger G, Hau P and Beier CP. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 2008; 68: 5706-5715.
33. Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M, Mitchell F, Jackman AL and Aboagye EO. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res. 2006; 66: 8558-8564.
34. Reichard P. Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem. 1988; 57: 349-374.
35. Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, Kaye FJ and Zajac-Kaye M. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell. 2004; 5: 341-351.
36. Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S and Allegra CJ. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA. 1991; 88: 8977-8981.
37. Kassis AL, Walicka MA and Adelstein SJ. Double-strand break yield following 125I decay-effects of DNA conformation. Acta Oncol. 2000; 39: 721-726.
38. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME and Silverman DH. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005; 46: 945-952.
39. Cornford EM and Oldendorf WH. Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim Biophys Acta. 1975; 394: 211-219.
40. Liebner S, Fischmann A, Rascher G, Duffner F, Grote EH, Kalbacher H and Wolburg H. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathologica. 2000; 100: 323-331.
41. Cheng Y, Morshed R, Cheng SH, Tobias A, Auffinger B, Wainwright DA, Zhang L, Yunis C, Han Y, Chen CT, Lo LW, Aboody KS, Ahmed AU and Lesniak MS. Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy. Small. 2013; 9: 4123-4129.
42. Beier F, Beier CP, Aschenbrenner I, Hildebrandt GC, Brümmendorf TH and Beier D. Identification of CD133(-)/telomerase(low) progenitor cells in glioblastoma-derived cancer stem cell lines. Cell Mol Neurobiol. 2011; 31: 337-343.
43. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier CP. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007; 67: 4010-4015.
44. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK and Fine HA. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006; 9: 391-403.
45. Kuczek T and Axelrod DE. Tumor cell heterogeneity: Divided-colony assay for measuring drug response. PNAS. 1987; 84: 4490-4494.